CiteAb 2019 Awards - Highly Commended Innovative Product of the Year - Bio-Rad's Anti-Ranibizumab-VEGF Antibody

Antibodies for bioanalysis and drug monitoring of ranibizumab and biosimilars

Develop highly selective and sensitive PK and ADA assays for the monoclonal antibody Fab fragment ranibizumab (Lucentis) using our range of ready-made anti-idiotypic antibodies.

  • Highly specific to ranibizumab or the ranibizumab-VEGF-A complex
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch to batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Ranibizumab was created from the same parent mouse antibody as bevacizumab (Avastin); it has four amino acid exchanges in the heavy chain and one amino acid exchange in the light chain compared to bevacizumab. Some of our anti-ranibizumab antibodies also detect bevacizumab (Table 1).

Table 1. Antibodies Specific to Ranibizumab.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Ranibizumab-VEGF-A

Complex Specific

Type 3

HCA304

AbD299281

Fab-FH4

1

PK ELISA antigen capture format

Order HCA304

Ranibizumab & Ranibizumab-VEGF-A

Non-Inhibitory Type 2

HCA306

AbD29858

Fab-FH4

18

PK ELISA antigen capture format

Order HCA306

HCA316
HCA316P

AbD29858_hIgG1

Human IgG1

HRP

18

PK ELISA antigen capture format

Order HCA316
Order HCA316P

HCA307

AbD298652

Fab-FH4

5

PK ELISA antigen capture format

Order HCA307

Ranibizumab

Inhibitory

Type 1

HCA305

AbD16746_hIgG13

Human IgG1

2

ADA control

Order HCA305

HCA185

AbD17976_hIgG1

Human IgG1

0.4

ADA control

Order HCA185

* Affinity measured in the monovalent Fab format
1 Also specific for the bevacizumab-VEGF-A complex

2 Also specific for bevacizumab and bevacizumab-VEGF-A complex

3 Also specific for bevacizumab

4 Monovalent Fab antibody DYKDDDDK- and His-6-tags


Anti-Ranibizumab-VEGF-A Complex Specific Antibody (Type 3)

This Type 3 monovalent Fab antibody recognizes the ranibizumab-VEGF complex; it does not bind to ranibizumab or VEGF-A alone. It is suitable as a detection antibody in a pharmacokinetic (PK) antigen capture ELISA, enabling detection of free drug.

Anti-Ranibizumab Non-Inhibitory Antibodies (Type 2)

The type 2 anti-ranibizumab antibodies bind to the ranibizumab idiotope, but do not inhibit the binding of ranibizumab to VEGF-A. They are suitable as a detection antibody in a PK antigen capture ELISA.

Anti-Ranibizumab Inhibitory Antibodies (Type 1)

The two Type 1 antibodies inhibit the binding of ranibizumab to its target VEGF-A, and therefore detect free drug. The antibodies are in fully human IgG1 format, and are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.


ELISA Protocols to Get You Started

PK Antigen Capture ELISAs

Fig. 1. Ranibizumab PK antigen capture ELISA using antibody HCA304.

Fig. 1. Ranibizumab PK antigen capture ELISA using antibody HCA304.

Schematic image of PK antigen capture ELISA with Type 3 antibody.

Schematic image of PK antigen capture ELISA with Type 3 antibody. Drug target (red), Fab fragment antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple).


Fig. 2. Ranibizumab PK antigen capture ELISA using antibody HCA307.

Fig. 2. Ranibizumab PK antigen capture ELISA using antibody HCA307.

Schematic image of PK antigen capture ELISA with Type 2 antibody

Schematic image of PK antigen capture ELISA with Type 2 antibody. Drug target (red), Fab fragment antibody drug (gold), non-inhibitory detection antibody, monovalent Fab format (purple).


Fig. 3. Ranibizumab PK antigen capture ELISA using antibody HCA316P.

Fig. 3. Ranibizumab PK antigen capture ELISA using antibody HCA316P.

 Schematic image of PK antigen capture ELISA with Type 2 antibody

Schematic image of PK antigen capture ELISA with Type 2 antibody. Drug target (red), Fab fragment antibody drug (gold), non-inhibitory detection antibody, Ig format (blue), labeled with HRP.


ADA Bridging ELISA

Fig. 4. Ranibizumab ADA bridging ELISA using antibody HCA305.

Fig. 4. Ranibizumab ADA bridging ELISA using antibody HCA305.

Schematic image of ADA bridging assay

Schematic image of ADA bridging assay. Monoclonal Fab fragment antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).


Related Product



Resources



Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.